Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-01-26 Governance Information
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
舆情管理制度
Governance Information Classification · 95% confidence The document is titled as a "舆情管理制度" which translates to "Public Opinion Management System" or "Crisis Management Policy". It is a detailed internal policy document approved by the company's board of directors, outlining procedures and responsibilities for managing public opinion and media crises. It does not contain financial data, earnings, audit information, or any shareholder meeting materials. It is not an announcement of a report but a governance-related internal regulation. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-01-26 Chinese
2024年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is titled as a '2024 Annual Performance Forecast Announcement' and contains preliminary financial data for the full year 2024 (January 1 to December 31). It explicitly states that the data are preliminary, unaudited, and subject to change in the final annual report. The document includes estimated net profit figures and explanations for performance changes, typical of an earnings preview or earnings release rather than a full annual report. The length is short (949 characters), and it is an announcement of preliminary results, not the full financial statements or detailed analysis. Therefore, it fits best as an Earnings Release (ER) rather than a full Annual Report (10-K) or Report Publication Announcement (RPA). FY 2024
2025-01-16 Chinese
关于通过日本GMP符合性检查的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the passing of the Japanese GMP compliance inspection for their product Celecoxib. It includes details about the certification, the issuing authority (PMDA), and the impact on the company. The document is short (774 characters) and serves as a regulatory announcement about compliance and certification rather than a financial report or detailed operational report. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-06 Chinese
关于使用闲置自有资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase wealth management products. It details the authorization, amounts, counterparties, risk controls, and investment terms related to the company's cash management activities. The document includes specific financial figures and dates but does not present comprehensive financial statements or a full financial report. It is a regulatory disclosure about capital management activities rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is about 5,028 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Hence, the classification is CAP with high confidence.
2025-01-05 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It details the authorization, amounts, counterparties, risk control, and investment specifics of these financial products. The document is a disclosure about the company's cash management and investment of idle raised funds, including compliance with stock exchange rules and risk warnings. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. The document is a regulatory announcement about capital management activities, specifically the use of idle raised funds for financial products, which fits the category of Capital/Financing Update (CAP). The document length is about 5,000 characters, and it is a full announcement, not just a notice of report publication. Therefore, the best classification is CAP with high confidence.
2025-01-05 Chinese
2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 third extraordinary general meeting of shareholders of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder meeting decisions and voting outcomes rather than presenting a full report or financial statements. The document length is short (1813 characters) and it is clearly a resolution announcement from a shareholder meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-12-24 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.